Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Besivance in Bacterial Conjunctivitis
NCT01175590Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Jun 2010
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bacterial conjunctivitis (BC) comparing Besivance with Vehicle (2 arms). Primary endpoints: Ocular Treatment Emergent Adverse Events at 7 days and Non-Ocular Treatment-Emergent Adverse Events at 7 days. Started Jun 2010; status: completed.
02
Drugs
besifloxacin
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT01175590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175590.